Search

 

Found 59 Results
Page 1 of 6


Aaron Gerlach, PhD


Aaron Gerlach, Ph.D., serves as our Director of Drug Discovery Alliances. He has been with Icagen since 2003, serving as a project lead for internal and collaborative research partnerships in addition to contributing to the development of Icagen’s business opportunities. Dr. Gerlach brings more than 25 years of ion channel target expertise and over 20

10.18.2022


Chris Silvia, PhD


Chris Silvia has more than 25 years of experience in the pharmaceutical and biotech industries. He began his employment with Icagen in Molecular Biology and Biochemistry, where he cloned and expressed ion channels and holds several patents related to ion channel molecular biology. Dr. Silvia has had increasing levels of responsibility in the information technology


Mark Chapman, PhD


Mark Chapman joined Icagen in 2000 and is currently a member of the leadership team. He has a great depth of expertise in ion channel biology and has led multiple internal drug discovery projects as well as programs with pharmaceutical partners. Dr. Chapman received a Doctorate of Pharmacology from Duke University and followed that with


Brett Antonio


Brett Antonio is currently Director of Biology and joined Icagen in 2000 following jobs at Novalon and Cubist Pharmaceuticals. He is a member of the Icagen leadership team and responsible for managing many aspects of biological assay development and execution, including HTS, plate-based pharmacology, molecular biology and cell culture. Mr. Antonio received his Bachelor of


Neil Castle, PhD


Neil Castle, PhD, has served as Icagen’s Vice President of Biology/Research since March 2016 and is a member of the senior leadership team overseeing the company’s biology activities. Prior to 2015, Icagen was part of Pfizer’s Neuroscience and Pain Research Unit, where Dr. Castle was Director of Biology and a member of the Pain Research


Anil Nair, PhD


Anil Nair joined Icagen in 2016 following a successful career at Sanofi, which began in 2001. During this time, Dr. Nair had positions of increasing responsibility including Global Coordinator for Structure, Design and Informatics. He is a member of the leadership team and coordinates all activities in computational chemistry, medicinal chemistry and in silico drug


Shetaun Deering, MBA


Shetaun Deering began her career with Icagen in July 1997. She assumed the position of Director of Operations in April 2020 and is a key member of the senior management team. Ms. Deering oversees high-level human resources duties, evaluating and continuously improving organizational policies and procedures to increase productivity and efficiency. In addition, Ms. Deering


Douglas Krafte, PhD


Douglas Krafte is Senior Vice President of Ion Channels/Transporters at OmniAb and serves as the Icagen Ion Channel Technology Site Head. Dr. Krafte has over 30 years of experience in the pharmaceutical and biotech industry managing research sites and R&D programs. Previously, he was Chief Scientific Officer at Icagen, Inc. and an executive officer there


Page 1 of 6